pharm edaily

[Shin-Min Joon, Edaily Reporter] DRTECH Eyes Turnaround with Strong Q1 Revenue Growth Targets Profitability by Q2 or Q3.

DRTECH CI. (Image=DRTECH)

Digital imaging diagnostics company DRTECH is showing signs of improved performance in 2025, led by a surge in revenue. The company aims to return to quarterly operating profit as early as the second quarter, or by the third quarter at the latest.

According to the securities industry on the 14th, DRTECH recorded 25.4 billion won in revenue for the first quarter of 2025, marking a 47% increase year-over-year. Operating loss narrowed from 4.6 billion won to 3.5 billion won during the same period.

A company official stated, “Sales of surgical imaging systems (C-arm), breast cancer diagnostic systems (mammography systems), and dental detectors have been strong since the beginning of the year, driving a significant increase in Q1 revenue,” adding “As a result, profitability has improved to some extent.”

DRTECH’s core business focuses on surgical imaging systems, mammography systems, dental detectors, and industrial detectors. Among these, the C-arm system has become a major driver of growth, offering real-time, high resolution digital imaging with minimal distortion, while maintaining the lowest radiation exposure globally?just one-fifth that of competing products.

Its industrial detectors are the first in the industry to implement a bendable (vendor-flexible) design. DRTECH’s dental video detectors are supplied to several leading domestic and international companies, including the world’s top dental diagnostic system manufacturer.

In 2025, DRTECH is pursuing both quantitative and qualitative growth. To support this strategy the company completed expansion investments at its Korean and Chinese production sites at the end of last year and began operations at the expanded facilities earlier this year. These upgrades have boosted production capacity by about 1.5 times.

The Korean plant will focus on diagnostic systems and high-end detectors while the Chinese facility will specialize in value-tier detector production. Beyond manufacturing expansion, DRTECH has also restructured its global footprint it relocated its U.S. office from Ohio to Atlanta, Georgia, and expanded its German subsidiary in Frankfurt.

Industry observers forecast that sales of DRTECH’s C-arm systems and dental detectors will more than double this year compared to 2024. Mammography system sales are also expected to increase by over 60%. The company recently launched a mobile intraoral diagnostic system (Intraoral CXT X-ray) as part of its ongoing efforts to broaden its imaging diagnostics lineup.

DRTECH representative said “Over the past year, we made significant investments in expanding our domestic and Chinese facilities, boosting R&D, and growing our workforce, We expect these efforts to begin delivering tangible results this year.”

The spokesperson added “Starting in Q2, we anticipate turning a quarterly profit and aim to achieve full year profitability in 2025.”